疫苗诱导的血栓形成和血小板减少症（VITT）；探索未知
Vaccine-induced thrombosis and thrombocytopenia (VITT); Exploring the unknown.
作者信息
Sunder Ashok, Saha Sudip, Kamath Sangita, Kumar Manish
机构信息
Department of Medicine, Tata Main Hospital, Bistupur, Jamshedpur, Jharkhand, India.
出版信息
J Family Med Prim Care. 2022 May;11(5):2231-2233. doi: 10.4103/jfmpc.jfmpc_2259_21!. Epub 2022 May 14.
Vaccination is supposed to be the most reliable means to end the COVID 19 pandemic, but recently there have been reports of thrombosis and thrombocytopenia in patients receiving the vaccine especially ChAdOx1 nCoV-19 (AstraZeneca University of Oxford and Serum Institute of India). This has been termed as vaccine-induced immune thrombotic thrombocytopenia (VITT), thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). This is a challenging situation and patients are treated with Fondaparinaux and Rivaroxaban after thrombocytopenia is corrected. Herewith, we report a case of VITT who presented to our hospital and was successfully treated over a weeks' time.
接种疫苗本应是结束新冠疫情的最可靠手段，但最近有报道称，接种疫苗的患者出现了血栓形成和血小板减少的情况，尤其是接种ChAdOx1 nCoV-19（牛津大学阿斯利康公司和印度血清研究所生产）疫苗的患者。这被称为疫苗诱导的免疫性血栓性血小板减少症（VITT）、血小板减少伴血栓形成综合征（TTS）和疫苗诱导的促血栓形成免疫性血小板减少症（VIPIT）。这是一个具有挑战性的情况，血小板减少症得到纠正后，患者会接受磺达肝癸钠和利伐沙班治疗。在此，我们报告一例VITT患者，该患者前来我院就诊，并在一周时间内成功治愈。
Zotero 插件